GlaxoSmithKline (NYSE:GSK) Stock Upgrade Equity analysts at the BofA Merrill equities division lifted shares of GlaxoSmithKline (NYSE:GSK) from a “Neutral” to a “Buy” on Wednesday,…
GlaxoSmithKline (NYSE:GSK) Stock Upgrade New York-listed GlaxoSmithKline (NYSE:GSK), was increased by equity analysts at BofA Merrill. The firm increased its rating on the $97.65 billion…
GlaxoSmithKline (NYSE:GSK) Rating Reaffirmed In a note sent to investors this morning, Argus reiterated their Buy rating on GlaxoSmithKline (NYSE:GSK) shares. The Estimated Target Price…
GlaxoSmithKline (NYSE:GSK) Rating Reaffirmed The brokerage firm has just set a target of $48 on GlaxoSmithKline (NYSE:GSK) shares. This is 19.20% from the previous close….
